Transcript Lupin Press Meet

Lupin Press Meet
October 7, 2003
Lupin Press Meet,
October 7, 2003
Background and Origin
Current Operations and Strengths
Recent Business Successes
Strategy for the Future
The Building Blocks
Glimpse into the Future
Lupin Press Meet,
October 7, 2003
Background and Origin
Lupin Press Meet,
October 7, 2003
Background and Origin





Started in 1968 by the Founder Chairman Dr
Desh Bandhu Gupta in Mumbai
Now spread over 6 locations in India and a
location in Thailand
Represented through Sales offices in UK,
USA, Hong Kong, Japan and CIS
Widely held and listed on all major Stock
Exchanges
3300 employees
Lupin Press Meet,
October 7, 2003
Current Operations and Strengths
Lupin Press Meet,
October 7, 2003
Current Operations






Among the top 6 Pharma companies in India
Turnover of Rs 1120 Cr and PBT of Rs 97 Cr
Integrated player with significant presence in both
API and Formulations
API Sales spread over more than 50 countries
globally
Strong Formulation Sales across India
1/3rd of Revenues from Exports
Lupin Press Meet,
October 7, 2003
Performance at a glance
CAGR 11%
CAGR 22%
1200
100
1000
80
800
2000-01
2001-02
2002-03
600
400
60
40
20
200
0
0
Sales
PBT
Rs’ crore
Lupin Press Meet,
October 7, 2003
Sales
PBT
2000-01
903
650
2001-02
957
964
2002-03
1120
971
Segment Trends
Formulations in India grew at 19 % in Q1 ( FY 03-04)
outperforming the market growth of 6 % as per ORG.
This segment will continue to be a growth driver.
Exports surged by 41 % and is expected to be the
leading growth driver in the future.
Regulated markets contribution to the company topline
stands at 31 % and is likely to grow further.
Lupin Press Meet,
October 7, 2003
Strengths





Increasing Presence in the Advanced markets of US and
Europe
9 out of 10 Plants are US FDA approved
Strong Integrated R&D program encompassing NCE,
NDDS and Process Research
World Leader in Anti TB
Strong Position in Cephalosporins and Cardiovasculars
Lupin Press Meet,
October 7, 2003
Recent Business Successes
Lupin Press Meet,
October 7, 2003
Recent Business Successes







Consolidation of our Presence in Advanced Nations
5 ANDAs filed and 3 approved
12 DMFs filed
First Generic formulation (Cefuroxime Axetil)
launched in US
110 patents filed and 50 granted
Ceff-ER, world’s first once a day Cephalexin
developed and launched
8 Brands in India’s top 300
Lupin Press Meet,
October 7, 2003
Strategy for the Future
Lupin Press Meet,
October 7, 2003
Strategy for the Future



Advanced Generic Mkts
 Expand APIs by partnering with niche players
 Grow formulations through Alliances
 Direct marketing of Branded formulations
API and Intermediates - In Domestic and
Developing markets by emphasizing on Cost
leadership and long term supply contracts
Formulations – In Domestic and Select Developing
markets through consolidating the Acute therapy
segments and building Chronic lifestyle segments
Lupin Press Meet,
October 7, 2003
The Building Blocks
Lupin Press Meet,
October 7, 2003
Building Blocks









Professionalization of Mgmt by inducting top notch senior
professionals
State of art IT initiative in place
Strong QA program in place
Focus on expanding capacity
Leveraging R&D strengths for Business
Comprehensive Process for Intellectual Property Management
Two World class Investors being inducted
Financial Restructuring
Slew of HR initiatives



Linkages with Strategy and Operations
Enhancing the Leadership pool
Very high degree of focus on Corporate Governance
Lupin Press Meet,
October 7, 2003
Glimpse into the Future
Lupin Press Meet,
October 7, 2003
Lupin of the Future







Be among top 3 pharma companies in India
Majority of Revenues from the Advanced markets
To have Higher and Sustainable earnings
R&D program to contribute significantly to the
Bottomline
Moving the Business Model up the Value Chain by
enhancing the Product and Geography Mix
To be known as a Venerable Institution rather than a
mere Organization
Maximizing Value for all Stakeholders
Lupin Press Meet,
October 7, 2003